No items found.
As of October 29, 2019, we moved our official headquarters from Prešov to Bratislava. MultiplexDX is now entirely situated in Comenius University Science Park at Ilkovičova 8, 841 04 Bratislava.
Peter Kilián, PhD., COO of MultiplexDX commented:
"We have had our laboratories in the Comenius University Science Park since 2018 but the headquarters were still in Prešov, which caused additional administrative issues. We're grateful to the management of the Science Park who accepted our request and we're happy that we were able to unify these two addresses and consequently streamline our operations. This will make life easier, especially for our suppliers, who won't need to think about where to deliver the goods."
The Science Park was opened in 2016 as a specialised research and development department of Comenius University and focuses on the fields of biomedicine, enviro-medicine and biotechnology. The infrastructure of the University Science Park is actively used by more than 180 staff members of the University and its partners. The project of establishing the Science Park was financed by the European Regional Development Fund, Operational Program Research and Development
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.